DELFLEX-LC/4.25% DEXTROSE (peritoneal dialysis solution no.8 with 4.25 % dextrose)

Drug overview for DELFLEX-LC/4.25% DEXTROSE (peritoneal dialysis solution no.8 with 4.25 % dextrose):

Generic name: peritoneal dialysis solution no.8 with 4.25 % dextrose
Drug class:
Therapeutic class: Renal Replacement Therapy

Peritoneal dialysis solutions are sterile solutions that produce osmotic and electrolytic gradients across the semipermeable peritoneal membrane.

Peritoneal dialysis is generally not intended for use as single therapy but only as an adjunct in the usual therapy of patients for whom dialysis is considered appropriate. The solutions are used during peritoneal dialysis for the removal of excess metabolites, for the management of serum electrolyte and/or fluid imbalances, and for the removal of toxic substances following acute overdosage. Peritoneal dialysis may be appropriate in patients with acute or chronic renal failure when usual therapy is determined to be inadequate.

Peritoneal dialysis is used in the management of intractable edema, hepatic coma, hypercalcemia, hyperkalemia, azotemia, or uremia. Peritoneal dialysis also may be used as an alternative to hemodialysis in the management of shock or circulatory collapse when the patient's artery-to-vein flow is inadequate. Peritoneal dialysis may also be used as an adjunct to hemodialysis in some patients.

Peritoneal dialysis has been used in the treatment of acute overdosage with dialyzable toxic substances when usual measures are inadequate or when such substances are known to be potentially nephrotoxic and/or cause acute renal dysfunction or failure; however, other methods of detoxification may be more effective than peritoneal dialysis for overdosage with many substances. Peritoneal dialysis solutions containing 1.5% dextrose may be used for the management of acute renal failure (including renal failure for which the cause has not yet been determined), uncontrolled hyperkalemia, or oliguria in the presence of a rapid catabolic rate, overhydration, or worsening of a patient's clinical condition in spite of appropriate therapy.

Peritoneal dialysis solutions containing decreased sodium concentrations (e.g., 131 mEq/L) are used to prevent postdialysis hypernatremia in hypertonic or short dialysis exchanges where fluid removal exceeds solute removal or in patients with severe hypernatremia. Peritoneal dialysis solutions containing acetate are used for dialysis therapy in patients with impaired lactate metabolism, including patients with hepatic dysfunction or impaired tissue perfusion. Solutions containing acetate are also used for dialysis therapy in patients with severe acidosis because of the higher concentrations of bicarbonate precursors in acetate-containing solutions compared with lactate-containing solutions (i.e., 45 versus 35 mEq/L).

Peritoneal dialysis solutions containing decreased magnesium concentrations (i.e., 0.5 mEq/L) are used for dialysis therapy in patients with hypermagnesemia or in patients in whom increased oral magnesium intake is desirable. Solutions containing decreased magnesium concentrations contain increased concentrations of lactate (40 mEq/L), the bicarbonate precursor, because of the decreased bicarbonate concentrations that frequently occur in patients with hypermagnesemia.